3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Oxaliplatin
95
Fluorouracil
84
Capecitabine
75
Gemcitabine
72
Leucovorin
68
Nivolumab
67
Bevacizumab
63
pembrolizumab
61
Magnetic Resonance Spectroscopy
52
Specimen Handling
50
Irinotecan
50
durvalumab
46
Radiotherapy
42
atezolizumab
40
Cisplatin
39
Paclitaxel
37
Biopsy
37
130-nm albumin-bound paclitaxel
34
Cetuximab
30
Carboplatin
27
Albumin-Bound Paclitaxel
26
Taxes
24
Drug Therapy
20
dehydroftorafur
19
Radiation
19
Ipilimumab
19
tislelizumab
18
Standard of Care
17
Docetaxel
17
trifluridine tipiracil drug combination
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Gastrointestinal
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled